When was Antheia founded?

Antheia was founded in 2013 and raised its 1st funding round 2 years after it was founded.

Where is Antheia located?

Antheia is headquartered in Palo Alto, United States. It is registered at Menlo Park, California.

Who is the current CEO of Antheia?

Christina Smolke of Antheia. They have also founded 1 company.

How many employees does Antheia have?

As of May 31, 2026, the latest employee count at Antheia is 66.

Is Antheia a funded company?

Antheia is a funded company, having raised a total of $176M across 13 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 13, 2015.

When was the latest funding round of Antheia?

Antheia's latest funding was a $***** Series C round on Jan 27, 2026, with participation from 3 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.3B in funding in 2026 to date.

Where does Antheia rank among its competitors?

Antheia ranks 15th amongst 2252 active competitors, of which 570 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Antheia?

Antheia's top competitors include Ginkgo Bioworks, Syngenta and Spark Therapeutics. Among them, Antheia secured the most recent funding round in January, 2026.

Antheia - 2026 Company Profile, Team, Funding & Competitors

Antheia is a series C company based in Palo Alto (United States), founded in 2013 by Christina Smolke and Kristy Hawkins. It operates as a Genetically engineered yeast cells to produce medicinal products. Antheia has raised $176M in funding from investors like Viking Global Investors, In-Q-Tel and AFF. The company has 2252 active competitors, including 570 funded and 406 that have exited. Its top competitors include companies like Ginkgo Bioworks, Syngenta and Spark Therapeutics.

Company Details

Antheia is focused on developing medicines using its technology. Its technology combines synthetic biology, informatics, and fermentation technology to provide plant-based medicines. It is currently working on engineering the yeast cells genetically to produce natural medicinal products.

Website: antheia.bio
Social
Registered Address: Menlo Park, California

Key Metrics

Founded Year

2013

Location

Palo Alto, United States

Stage

Series C

Total Funding

$176M in 13 rounds

Latest Funding Round

Series C, Jan 27, 2026, $*****

Investors

Viking Global Investors & 16 more

Ranked

15^th among 2252 active competitors

Employee Count

66 as on May 31, 2026

Investment & Acquisitions

Atomic AI

Similar Companies

Ginkgo Bioworks & 2805 more

View Antheia's full profile

Antheia is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ANTHEIA ENGINEERS PRIVATE LIMITED CIN: U70100DL2012PTC236447 , India, Active	May 25, 2012	0 - ₹10 Cr (As on Mar 31, 2025)	-
ANTHEIA INC CIN: 462857357 , United States, Active	Dec 26, 999	-	50 (As on Dec 31, 2022)	-

Antheia has raised a total funding of $176M over 13 rounds. Its first funding round was on Mar 13, 2015. Its latest funding round was a Series C round on Jan 27, 2026 for $*****. 3 investors participated in its latest round. Antheia has 17 institutional investors.

Here is the list of recent funding rounds of Antheia:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 27, 2026	1893362	Series C	6689275	7401120	3186135	6799383
Jun 03, 2025	7600664	Series C	9707574	1873648	9858333	EDBI & 7 more
Jul 21, 2024	6198732	Series B	8270686	6273254	In-Q-Tel & 2 more	9666264

Access funding benchmarks and valuations. Sign up today!

View details of Antheia's funding rounds and investors

The founders of Antheia are Christina Smolke and Kristy Hawkins. Christina Smolke is the CEO of Antheia.

Here are the details of Antheia's key team members:

Christina Smolke: Co-Founder & CEO of Antheia.
Kristy Hawkins: Co-Founder & CSO of Antheia.
Contact Info: 1 email address

Antheia's Board of Directors

Antheia's board has 4 active members. Ram Shriram, Valerie Minassian, Catherine Thodey and Christina D. Smolke are independent board members.

Here is the list of Antheia's board of directors:

Name	Type	Representing	Status	Duration
Ram Shriram	Independent board member	-	Current	11y 3m
qniizsv	Independent board member	-	Current	4y 9m
ducvapc	Independent board member	-	Current	5y 6m
niggorj	Independent board member	-	Current	9y 3m

View details of Antheia's Founder profiles and Board Members

Antheia's employee count trend

Antheia has 66 employees as of May 26. Here is Antheia's employee count trend over the years:

Uncover Antheia's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Antheia include Ginkgo Bioworks, Syngenta and Spark Therapeutics. Here is the list of Top 10 competitors of Antheia, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Ginkgo Bioworks 2008, Boston (United States), Public	Autonomous labs for biotechnology, empowering scientists to design the living world	$796M	Viking Global Investors, T. Rowe Price & 53 others	81/100
2nd	Syngenta 2000, Basel (Switzerland), Acquired	Developer of technologies and sustainable farming practices for farmers	-	Analah Ventures, Europa	75/100
3rd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
4th	Twist Bioscience 2013, San Francisco (United States), Public	Developer of a semiconductor-based DNA synthesis platform	$321M	Fidelity Investments, Foresite Capital & 39 others	72/100
5th	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, Perceptive Advisors & 30 others	71/100
6th	Beam Therapeutics 2017, Cambridge (United States), Public	Developer of gene therapy using CRISPR base editing to treat diseases	$222M	Google Ventures, Cormorant-asset & 16 others	71/100
7th	Orchard Therapeutics 2015, London (United Kingdom), Acquired	Developer of gene therapies for treating rare diseases	$440M	Baillie Gifford, ORI Capital & 30 others	70/100
8th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
9th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	Fidelity Investments, T. Rowe Price & 9 others	69/100
10th	Codexis 2002, Redwood City (United States), Public	Developer of high-performance enzymes for drug discovery	$111M	EDBI, Casdin Capital & 12 others	68/100
15th	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	EDBI, In-Q-Tel & 15 others	67/100